Lakefront Biotherapeutics (LKFT) Retained Earnings (2014 - 2026)
Lakefront Biotherapeutics (LKFT) reported Retained Earnings of -$10.1 million for Q1 2026, down 86.0% year-over-year from -$72.1 million in Q1 2025, and little changed quarter-over-quarter from -$10.1 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Retained Earnings (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 13 years of Retained Earnings data on file, last reported at -$10.1 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$10.1 million, down 86.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.1 million (down 86.0% YoY), and the FY2025 annual result was -$10.1 million, up 92.99% from the prior year.
- Retained Earnings was little changed at -$10.1 million in Q1 2026 per LKFT's latest filing, from -$10.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$5.0 million in Q4 2022 and troughed at -$143.5 million in Q4 2024.
- A 5-year average of -$18.3 million and a median of -$7.7 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings surged 98.82% in 2022, then slumped 2164.67% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$5.0 million in 2022, then slipped by 27.99% to -$6.3 million in 2023, then plunged by 2164.67% to -$143.5 million in 2024, then surged by 92.99% to -$10.1 million in 2025, then declined by 0.47% to -$10.1 million in 2026.
- Business Quant data shows LKFT's Retained Earnings at -$10.1 million in Q1 2026, -$10.1 million in Q4 2025, and -$10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -838.07 Mn |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | -10.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.10 Mn |
| Dec 31, 2025 | -10.05 Mn |
| Sep 30, 2025 | -10.86 Mn |
| Jun 30, 2025 | -10.43 Mn |
| Mar 31, 2025 | -5.43 Mn |
| Dec 31, 2024 | -143.52 Mn |
| Sep 30, 2024 | -7.73 Mn |
| Mar 31, 2024 | -6.01 Mn |
| Dec 31, 2023 | -6.34 Mn |
| Sep 30, 2023 | -5.37 Mn |
| Mar 31, 2023 | -5.15 Mn |
| Dec 31, 2022 | -4.95 Mn |
| Mar 31, 2022 | -11.48 Mn |
| Dec 31, 2021 | -420.07 Mn |
| Jun 30, 2021 | -12.97 Mn |
| Dec 31, 2020 | -13.00 Mn |
| Jun 30, 2020 | -5.40 Mn |
| Mar 31, 2020 | -5.43 Mn |
| Dec 31, 2019 | -120.90 Mn |
| Sep 30, 2019 | -817,856.57 |